Search

Displaying results 9491 - 9500 of 10000 in total
  1. Drug

    Entospletinib

    go.drugbank.com/drugs/DB12121
    Investigational

    Entospletinib has been used in trials studying the treatment of Oncology, Follicular Lymphoma, B-cell Malignancies, Mantle Cell Lymphoma, and Non-Hodgkin Lymphoma, among others.

  2. Drug

    CMX-2043

    go.drugbank.com/drugs/DB12795
    Investigational

    CMX-2043 has been used in trials studying the treatment and prevention of Non STEMI, Unstable Angina, Stable Coronary Artery Disease, and Percutaneous Coronary Intervention.

  3. Drug

    Ethoheptazine

    go.drugbank.com/drugs/DB08988
    ApprovedWithdrawn

    It was invented in the 1950s and is related to other drugs such as proheptazine. Ethoheptazine is no longer marketed in the United States.

  4. Drug

    Trevogrumab

    go.drugbank.com/drugs/DB15159
    Investigational

    Trevogrumab is under investigation in clinical trial NCT02943239 (Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women

  5. Drug

    G305

    go.drugbank.com/drugs/DB17292
    Investigational

    G305 is a [recombinant NY-ESO-1 protein] plus glucopyranosyl lipid A (GLA) in a stable emulsion (SE). G305 is an active component of CMB305 along with [LV305].[L47346]

  6. Drug

    Apricoxib

    go.drugbank.com/drugs/DB12378
    Investigational

    Apricoxib has been used in trials studying the treatment and prevention of Lung Cancer, Breast Cancer, Pancreatic Cancer, Non Small Cell Lung Cancer, and Metastatic Pancreatic Cancer, among others.

  7. Drug

    Sonolisib

    go.drugbank.com/drugs/DB12601
    Investigational

    Sonolisib has been used in trials studying the treatment of Glioblastoma, Prostate Cancer, Advanced Solid Tumors, Advanced BRAF-mutant Cancers, and Non Small Cell Lung Cancer (NSCLC), among others.

  8. Drug

    VB2-011

    go.drugbank.com/drugs/DB05411
    Experimental

    VB2-011 is an antibody developed as an anti-cancer treatment. According to some preclinical studies, it has a potential to inhibit tumour growth in various cancers including lymphoma and melanoma.

  9. Drug

    CYC116

    go.drugbank.com/drugs/DB05198
    Investigational

    Cyclacel's small molecule investigational drug, CYC116, is the third orally-available Cyclacel drug to enter development, which demonstrated anticancer activity with a mechanism consistent with inhibition of … In preclinical studies, CYC116 has demonstrated antitumor activity in both solid tumors and hematological cancers.

  10. Drug

    IL15-NK Cell

    go.drugbank.com/drugs/DB15725
    Investigational

    In particular, incubation with IL-15 allows NK cells to lyse a broad range of fresh and cultured tumor targets that the cell is not normally sensitive to.